Global upper GI series Market Size, Share, Forecast Report, 2020-2027

An upper gastrointestinal (GI) series is also known as contrast radiography or upper gastrointestinal study, which is performed to detect abnormalities and diseases of GI tract. In this procedure, a contrast media is ingested or imparted into the digestive tract and X-rays are used to create radiographs of the desired portion. According to the National Institute of Diabetes and Digestive and Kidney Diseases, in 2010 approximately 60 to 70 million people were affected by major or minor GI diseases. This number is continuously increasing due to poor diet and increasing aging population. The global GI series market is driven mainly by increasing prevalence of GI diseases & gastric cancer, and changing lifestyle. Developments in the technologies, cost-effective methods, increasing aging population and government support for research have also affected the growth of the market positively. Whereas, availability of alternative therapies and limited applications of the method have hampered the growth of the market.
Segmentation:

The global upper GI series market is segmented on the basis of test type, into standard barium upper GI series and double-contrast upper GI series. On the basis of imaging material, the market is segmented into: barium swallow, barium meal, and barium follow-through. On the basis of application, the market is segmented into: esophageal reflux, esophageal varices, ulcers, hiatal hernias, and others. On the basis of end users, it is segmented into: hospitals, clinics & laboratories, and other
Key Players for global upper GI series market:

GastroIntestinal Specialists LLC. (UK), Eisai Co., Ltd (Japan), Cadila Pharmaceuticals Limited (India), Purdue Pharma L.P. (US), Alfa Wassermann SPA (Germany), Novadaq Technologies Inc. (Canada), AstraZeneca (UK), Ironwood Pharmaceuticals Inc. (US) and others.